Dermatologic Therapy最新文献

{"title":"Global Analysis and Latest Research Hot Spots of Silicone Applications and Advantages: A Bibliometric Analysis and Visualized Review","authors":"Houriah Y. Nukaly,&nbsp;Abdulaziz F. Samandar,&nbsp;Ibrahim R. Halawani,&nbsp;Muna F. Al Naim,&nbsp;Abdulrahman Alrashed,&nbsp;Nawaf Aljehani,&nbsp;Batool Y. Alturaiki,&nbsp;Ghassan Barnawi,&nbsp;Ammar Alsayegh,&nbsp;Abdulhadi Jfri","doi":"10.1155/dth/7809849","DOIUrl":"https://doi.org/10.1155/dth/7809849","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Silicone-based materials have been widely used across multiple medical and surgical disciplines owing to their favorable physical and biological properties. In addition to their established role in scar prevention and management, silicone applications extend to wound care, pressure ulcer prevention, reconstructive and aesthetic surgery, implantable devices, and biomaterial development. In clinical practice, silicone gel sheets exert their effects primarily through occlusion and normalization of transepidermal water loss rather than hydration, contributing to improved tissue healing and scar maturation. Despite the broad and expanding use of silicone in healthcare, a comprehensive bibliometric evaluation of global research trends, influential studies, and research hotspots in this field remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A search in the Web of Science Core Collection (WoSCC) using the keywords “silicone gel,” “silicone sheet,” and “silicone dressing” identified 758 articles published from January 1, 2000, to September 1, 2024. The final dataset comprised 547 articles, which were analyzed using VOSViewer, Excel, and Drawio to create visual maps.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The United States led global publications with 125 publications, followed by China with 95 documents. The most productive author was “W.G. Stevens.” The most productive and cocited journal was Plastic and Reconstructive Surgery Journal.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Silicone gel and sheets are highly effective in scar management. This research on silicone reveals that the highest keyword occurrences include “Breast,” “Scar,” and “Pressure ulcer” providing valuable insights into the trends and progress in silicone research, not only for scar management but also for pressure ulcer prevention.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7809849","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, Serological, and Flowcytometric Predictors of Pemphigus Relapse After Rituximab: A Retrospective Study","authors":"Simone Liguori,&nbsp;Francesca D’Elia,&nbsp;Dario Didona,&nbsp;Noemi Coppola,&nbsp;Daniela Adamo,&nbsp;Maddalena Raia,&nbsp;Michele Davide Mignogna,&nbsp;Stefania Leuci","doi":"10.1155/dth/8655024","DOIUrl":"https://doi.org/10.1155/dth/8655024","url":null,"abstract":"<p>Rituximab (RTX) has significantly improved pemphigus vulgaris (PV) management. Nonetheless, the risk of post-RTX flare is high. This study aimed to identify clinical, serological, and immunological predictors of relapse (R) after RTX therapy. Forty-four PV patients treated with RTX were enrolled. Baseline clinical characteristics were collected, and anti-Dsg antibodies levels were evaluated before and after therapy. Peripheral blood flowcytometry was used to assess CD20+ and CD4+ cell frequencies at baseline, at 3-month intervals until B-cell repopulation, at B-cell repopulation time, at 6 and 12 months after repopulation, and at the end of follow-up or at R. Relapsing patients reported lower levels of CD4+ cells at B-cell repopulation time and increasing postrepopulation T-cell values compared to patients experiencing remission. Post-RTX T-cell course was found to correlate with anti-Dsg antibodies titers with the maximum increase of anti-Dsg3 value coinciding with the peak in CD4+ T-cell frequency. Additionally, patients initially responding to conventional immunosuppressants reported higher CD4+ T-cell levels both at baseline and at B-cell repopulation time and a significantly lower risk of post-RTX R. Post-RTX CD4+ T-cell values were found to predict patients’ clinical response and to correlate with autoantibodies levels. Flowcytometric T-cell immunophenotyping could be proposed as an additional prognostic marker.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8655024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Survival to Side Effects: Retrospective Analysis of Adverse Events in Checkpoint Inhibitor Therapy for Melanoma Using the FAERS Database","authors":"Dorra Guermazi,&nbsp;Matthew Liu,&nbsp;Elie Saliba","doi":"10.1155/dth/7255428","DOIUrl":"https://doi.org/10.1155/dth/7255428","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Checkpoint inhibitors have significantly advanced melanoma treatment but are associated with a broad spectrum of adverse events (AEs), some of which are severe or fatal.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to analyze AE patterns across PD-1, PD-L1, CTLA-4, and LAG-3 checkpoint inhibitors in melanoma, focusing on usage trends, AE severity, fatality reporting outcomes, and geographic distribution.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We conducted a retrospective study using data from the FDA Adverse Event Reporting System (FAERS) database, analyzing cases from January 2006 to December 2024. Descriptive statistics were used to evaluate AE severity, fatality reporting frequency, and geographic distribution. Additional analyses included combination therapy subgroup analyses, disproportionality analysis of selected immune-related adverse events, multivariable logistic regression, and event-to-report lag analysis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;PD-1 inhibitors, especially pembrolizumab and nivolumab, had the highest number of reported cases and serious AEs (85.54% and 92.1%, respectively). Fatal outcomes were reported in 20.61% of pembrolizumab cases. However, FAERS data do not allow differentiation between deaths attributable to drug-related toxicity versus underlying disease progression. Tremelimumab had the highest reports of fatality among CTLA-4 inhibitors (53.66%). Relatlimab was associated with myocarditis. PD-1 inhibitors and atezolizumab had a higher proportion of foreign cases. Combination therapy was associated with higher odds of serious AEs for nivolumab, ipilimumab, and relatlimab, while the foreign reporting region was frequently associated with higher odds of fatal outcomes.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Limitations&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The study is subject to reporting biases, and although multivariable regression was used to adjust for available covariates, FAERS lacks detailed clinical information, including comorbidities, treatment duration, and disease severity.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Checkpoint inhibitors have transformed melanoma management but are associated with substantial immune-related AEs. Our findings highlight the importance of dermatologic surveillance as an integral component of immunotherapy care. As immunotherapy use continues to","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7255428","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Bimekizumab Without an Induction Regimen in Patients With Moderate-to-Severe Plaque Psoriasis: A Real-World Clinical Practice Study","authors":"José Ángel Domínguez García,&nbsp;Jorge Alonso Suárez Pérez,&nbsp;Antonio Zamora Ruiz,&nbsp;Pedro José Navarro Guillamón,&nbsp;Silvia Habicheyn Hiar,&nbsp;Rosa María Castillo Muñoz,&nbsp;Enrique Herrera Acosta","doi":"10.1155/dth/8672172","DOIUrl":"https://doi.org/10.1155/dth/8672172","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In clinical practice, some patients present with moderate baseline inflammatory burden (Psoriasis Area and Severity Index [PASI] 5–10), in whom the need for an induction phase with bimekizumab remains uncertain. The aim was to evaluate, under real-world conditions, whether initiating treatment without an induction regimen allows comparable clinical responses in patients with lower baseline inflammatory burden.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective observational study was conducted including 65 adult patients with moderate-to-severe plaque psoriasis treated with bimekizumab with an induction regimen (<i>n</i> = 39) or without induction (<i>n</i> = 26) and followed for 24 weeks. The noninduction strategy was preferentially used in patients with lower baseline inflammatory activity according to clinical judgment. Clinical efficacy outcomes were analysed at baseline and Week 24, with PASI90 as the primary endpoint, and adverse events and treatment discontinuations were also recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Baseline PASI was higher in the induction group (12.3 ± 4.2) than in the noninduction group (6.9 ± 2.5; <i>p</i> &lt; 0.001). At Week 24, mean PASI was 0.70 ± 1.05 in the induction group and 0.40 ± 0.49 in the noninduction group. PASI90 response rates were 69% and 73%, respectively (<i>p</i> = 0.79). The overall incidence of mucocutaneous candidiasis was 9.2% (6/65), occurring exclusively in the induction group (15.4% vs 0%; <i>p</i> = 0.03). Two patients required discontinuation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In patients with lower baseline inflammatory burden, a noninduction strategy achieved high clinical responses comparable to the standard induction regimen at 24 weeks. Lower drug exposure may be associated with a favourable safety profile in selected patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8672172","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Expression of ERG, CD31, CD34, and D2-40 in Representative Vascular Tumors and Lymphatic Malformation-Associated Lesions-A Retrospective Study","authors":"Lurun Wang,&nbsp;Chao Ji,&nbsp;Bo Cheng,&nbsp;Ziping Zhang,&nbsp;Jinwen Huang,&nbsp;Xianhui Wang","doi":"10.1155/dth/5436659","DOIUrl":"https://doi.org/10.1155/dth/5436659","url":null,"abstract":"<p>The distinction between vascular anomalies is clinically challenging due to their similar clinical presentations and pathological features. This study assessed the immunohistochemical expression of ERG, CD31, CD34, and D2-40 in representative vascular tumors and lymphatic malformation-associated lesions to evaluate their diagnostic value and inform clinical diagnosis. A retrospective analysis of 53 cases spanning from 2012 to 2017 was performed, encompassing angiokeratoma, pyogenic granuloma, Kaposi’s sarcoma, and angiosarcoma. In the analysis of this research, ERG was weakly positive in angiokeratoma with a low positive rate, while CD31 and CD34 showed high sensitivity and specificity with strong positive staining in all tumor groups. D2-40 showed negative expression in pyogenic granuloma but was positive in other tumor types, indicating higher specificity in lymphatic-derived tumors. Notably, the positive rate for ERG in angiokeratoma was significantly lower compared to other tumor groups, and CD31 and CD34 maintained higher positive rates across all groups. Conversely, the positive rate for D2-40 in pyogenic granuloma was markedly lower than that in angiokeratoma, Kaposi’s sarcoma, and angiosarcoma, suggesting its potential as a diagnostic marker for lymphatic endothelial specificity. Overall, these findings underscore the utility of ERG, CD31, CD34, and D2-40 as markers for differential diagnosis of vascular tumors and lymphatic malformation-associated lesions.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5436659","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuropsychological and Psychiatric Outcomes During Isotretinoin Treatment in Adolescents With Acne Vulgaris: A Single-Arm Prospective Cohort Study","authors":"Hansa Betül Öz Genişoğlu,&nbsp;Buse Akıncı,&nbsp;Tuna Sezer,&nbsp;Mualla Polat,&nbsp;Yasemin İmrek,&nbsp;Mesut Sari,&nbsp;Ali Evren Tufan","doi":"10.1155/dth/3463004","DOIUrl":"https://doi.org/10.1155/dth/3463004","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acne vulgaris (AV) is a common condition in adolescents and is associated with significant psychosocial burden. Isotretinoin (ISO) is highly effective for AV, but concerns remain regarding its psychiatric and neurocognitive effects. This study aimed to evaluate the neuropsychological and psychiatric outcomes of ISO treatment in adolescents and to explore their associations with inflammatory markers. Although the psychiatric effects of ISO have been extensively investigated, comprehensive prospective studies evaluating both psychiatric and neuropsychological outcomes in adolescents with AV are limited. Therefore, this study aimed to comprehensively assess these domains during ISO treatment using a broad assessment battery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective study, 78 adolescents aged 13–18 years with severe or treatment-resistant AV were assessed at baseline and after 3 months of ISO treatment. Psychiatric status was evaluated using structured interviews (K-SADS-PL) and the RCADS-CV. Neuropsychological performance was assessed using the Stroop Color Word Test, Visual-Auditory Digit Span, and Digit Span Learning Test. Acne severity (GAGS) and inflammatory markers (NLR, PLR) were also measured.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ISO treatment resulted in a significant reduction in acne severity without evidence of neuropsychological decline. A modest improvement in interference control was observed. Internalizing symptoms, particularly depressive and anxiety symptoms, increased during treatment, especially in the imputed analysis. No significant associations were found between inflammatory markers and neuropsychological or psychiatric outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>ISO treatment in adolescents with AV appears to be neurocognitively safe, but internalizing symptoms increased during treatment. These findings highlight the importance of monitoring psychiatric symptoms during treatment. Further controlled studies are needed to confirm these results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3463004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective Study of the Effects of Isotretinoin on Depression, Anxiety, and Suicidal Ideation","authors":"Samet Bayazit,&nbsp;Zekayi Kutlubay","doi":"10.1155/dth/5899771","DOIUrl":"https://doi.org/10.1155/dth/5899771","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit. The association between isotretinoin treatment and depression, anxiety, and suicidal ideation remains controversial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>In this prospective study, 143 patients with moderate-to-severe acne (mean age: 21.9 ± 4.5 years) were enrolled. Patients were divided into two groups: systemic isotretinoin and a control group. Depression, anxiety, and suicidal ideation were assessed at baseline and at the 2nd and 4th months with the Beck Depression and Beck Anxiety Scales.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both groups showed significant reductions in mean depression and anxiety scores at the 4th month compared to baseline. No significant differences in depression and anxiety severity were found between the isotretinoin and control groups at baseline, 2nd, or 4th month. Suicidal ideation occurred in four patients in the isotretinoin group, most of whom had baseline psychiatric risk factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this study, isotretinoin treatment for moderate-to-severe acne was not associated with an increase in symptoms of depression or anxiety; in contrast, depression and anxiety scores decreased over time, similar to the control group. Large prospective studies with both pre- and posttreatment follow-up are needed to evaluate isotretinoin and the risk of suicidal ideation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5899771","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monocyte Counts in Peripheral Blood are Linked to Treatment Outcomes in Chronic Spontaneous Urticaria","authors":"Lei Zhu,&nbsp;Qiaozhi Cao,&nbsp;Cong Peng,&nbsp;Yun Li,&nbsp;Runqiu Liu,&nbsp;Jie Li","doi":"10.1155/dth/2509575","DOIUrl":"https://doi.org/10.1155/dth/2509575","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic spontaneous urticaria (CSU) is a relapsing, immune-mediated skin disease. However, the role of monocytes in its pathogenesis and clinical significance remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to investigate the correlation between peripheral blood monocyte counts and clinical features in CSU patients, as well as to explore their potential predictive value for the therapeutic efficacy of second-generation H1-antihistamines (sgAHs) and omalizumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two independent patient cohorts were included: Cohort 1 was utilized to evaluate sgAHs treatment efficacy, while Cohort 2 was employed to analyze omalizumab efficacy in CSU patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 656 and 105 CSU patients were enrolled in Cohort 1 and Cohort 2, respectively. Baseline peripheral blood monocyte levels were significantly associated with treatment outcome in both cohorts (OR = 0.005, <i>p</i> &lt; 0.001; OR = 0.07, <i>p</i> = 0.005, respectively). Furthermore, compared to baseline levels, peripheral blood monocyte counts decreased significantly in both cohorts (<i>p</i> &lt; 0.0001 and <i>p</i> = 0.0205, respectively). In Cohort 2, fast-responders, but not slow-responders or non-responders, exhibited a significantly greater reduction in monocyte counts post-treatment (<i>p</i> = 0.0031 for fast-responders, <i>p</i> = 0.5285 for slow-responders, and <i>p</i> = 0.7565 for non-responders, respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Baseline monocyte counts were significantly correlated with the therapeutic efficacy of both sgAHs and omalizumab in CSU patients.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Chinese Clinical Trial Registry: ChiCTR-OCH-14004518</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2509575","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a Competing-Risk Nomogram for Predicting Cause-Specific Mortality in Cutaneous Verrucous Carcinoma: A Retrospective SEER-Based Study","authors":"Siomui Chong,&nbsp;Liying Huang,&nbsp;Yu-Yen Yang,&nbsp;Santosh Chokkakula,&nbsp;Yuyi Ou,&nbsp;Xiaoxi Zhang,&nbsp;Jiang Yong,&nbsp;Tingting Lau,&nbsp;Ying Zhou,&nbsp;Xiaohua Xu,&nbsp;Chi-Chien Ho,&nbsp;Changxu Han,&nbsp;Jun Lyu,&nbsp;Zhenying Zhang","doi":"10.1155/dth/3157109","DOIUrl":"https://doi.org/10.1155/dth/3157109","url":null,"abstract":"<p>This retrospective observational cohort study aimed to develop and validate competing-risk nomograms for predicting cancer-specific survival (CSS) and noncancer-specific death (OCD) in patients with cutaneous verrucous carcinoma (CVC). Data were extracted from the SEER database, including 649 eligible patients diagnosed between 2004 and 2015 across 18 U.S. regions. Competing-risk analyses were performed using the cumulative incidence function, Gray’s test, and the Fine–Gray model. Nomograms were constructed to estimate 3-, 5-, and 8-year probabilities of CSS and OCD. Model performance was evaluated using the C-index, IDI, NRI, calibration curves, and decision curve analysis. The results showed low cumulative incidence of CSS (3-, 5-, and 8-year: 3.08%, 3.88%, and 4.20%) and higher OCD rates (7.6%, 13.3%, and 19.6%). Significant prognostic factors for CSS included age, race, surgery, AJCC stage, and marital status, while age and marital status were associated with OCD. The models demonstrated good discrimination (C-index: 0.703 for CSS and 0.714 for OCD) and outperformed AJCC staging alone. Calibration curves confirmed strong agreement between predicted and observed outcomes. In conclusion, these competing-risk nomograms provide accurate individualized survival prediction and may aid clinical decision-making in CVC patients.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3157109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Imiquimod in Mycosis Fungoides: A Systematic Review of Published Clinical Evidence","authors":"Kerem Balan,&nbsp;Feyza Nur Akcin Balan","doi":"10.1155/dth/2562372","DOIUrl":"https://doi.org/10.1155/dth/2562372","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Topical imiquimod has been used as a skin-directed treatment in selected patients with mycosis fungoides, but the available evidence remains limited and scattered across case reports, case series, pilot studies, retrospective cohorts, and preliminary conference data.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To systematically review the published clinical evidence on topical imiquimod in mycosis fungoides, with emphasis on treatment settings, regimens, outcomes, tolerability, and durability of response.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A systematic review was performed according to PRISMA principles. PubMed and Scopus were searched from database inception to April 2026 to identify publications reporting topical imiquimod use in histopathologically confirmed mycosis fungoides. Eligible publications included case reports, case series, pilot studies, retrospective cohorts, and conference abstracts with extractable imiquimod-specific clinical outcome data. Because of marked heterogeneity in study design, disease stage, treatment schedules, follow-up duration, and outcome reporting, the data were synthesized qualitatively.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Fifteen studies comprising 47 imiquimod-treated patients or patients with MF-related entities were included. Evidence consisted mainly of individual case reports and small case series, supplemented by pilot studies, retrospective cohorts, and one recent conference abstract. Topical imiquimod was most commonly used for localized, treatment-refractory, or anatomically challenging lesions, including plaque-stage, folliculotropic, and tumor-stage mycosis fungoides. Clinical improvement, including complete or near-complete clearance in selected reports, was described most often in localized or refractory disease. In larger observational studies, reported overall response rates were more modest, ranging from approximately 50%–60%, with complete clearance reported in 40% in one recent cohort. Local inflammatory reactions were commonly reported; however, their association with clinical improvement remains observational and cannot be interpreted as evidence of causality.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Topical imiquimod may represent a potential individualized skin-directed approach for selected patients with localized or treatment-refractory mycosis fungoides. However, the current evidence remains limited, heterogeneous, predominantly","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2562372","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148784474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}